Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2020’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

– The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects

– The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

21st Century Therapeutics Inc

Advanced Innovative Partners Inc

Advenchen Laboratories LLC

Amryt Pharma Plc

Angion Biomedica Corp

Atox Bio Ltd

BCN Biosciences LLC

BioCurity Pharmaceuticals Inc

BioIncept LLC

Bolder Biotechnology Inc

Cellphire Inc

Ceramedix Holding LLC

Ceramide Therapeutics LLC

Chrysalis BioTherapeutics Inc

Cleveland BioLabs Inc

Consegna Pharma Inc

Creative Medical Technology Holdings Inc

Daiichi Sankyo Co Ltd

Eagle Pharmaceuticals Inc

Enzychem Lifesciences Corp

Exponential Biotherapies Inc

Extend Biosciences Inc

Fibreu Ltd

FirstString Research Inc

Foresee Pharmaceuticals Co Ltd

Genexine Inc

GNI Group Ltd

Humanetics Corp

Inflammatory Response Research Inc

iNtRON Biotechnology Inc

Jay Pharma Inc

KannaLife Sciences Inc

Luxena Pharmaceuticals Inc

Matrix Biomed Inc

Meabco AS

Medesis Pharma SA

Neumedicines Inc

New Amsterdam Sciences Inc

Nohla Therapeutics Inc

Novartis AG

Noveome Biotherapeutics Inc

Onconova Therapeutics Inc

Original BioMedicals Co Ltd

P2D Inc

PharmaIN Corp

Phoenicia Biosciences Inc

Pluristem Therapeutics Inc

RDD Pharma Ltd

RepoCeuticals ApS

RxBio Inc

Soligenix Inc

Sunny Pharmtech Inc

Synedgen Inc

Therapeutic Systems Research Laboratories Inc

TheraSource LLC

Tonix Pharmaceuticals Holding Corp

Valenta Pharm

Worphmed Srl

Table of Contents

Table of Contents

Introduction

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by 21st Century Therapeutics Inc, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Advanced Innovative Partners Inc, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Advenchen Laboratories LLC, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Amryt Pharma Plc, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Angion Biomedica Corp, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Atox Bio Ltd, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by BCN Biosciences LLC, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2020 (Contd..2), H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2020 (Contd..3), H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2020 (Contd..4), H1 2020

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports